Thu, Sep 18, 2014, 8:28 AM EDT - U.S. Markets open in 1 hr 2 mins

Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • weightbayou weightbayou Apr 24, 2013 6:29 PM Flag

    Kot/J/Nesh et al - Celldex and Genentech paper

    Published April 8, 2013
    The Rockefeller University Press, doi: 10.1084/jem.20121251
    © 2013 Cohn et al.
    Article
    Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation
    Lillian Cohn1, Bithi Chatterjee1, Filipp Esselborn1, Anna Smed-Sörensen1,2, Norihiro Nakamura1, Cécile Chalouni1, Byoung-Chul Lee1, Richard Vandlen1, Tibor Keler3, Peter Lauer4, Dirk Brockstedt4, Ira Mellman1, and Lélia Delamarre1
    + Author Affiliations
    1Genentech, South San Francisco, CA 94080
    2Karolinska Institutet, 171 77 Solna, Sweden
    3Celldex Therapeutics Inc., Phillipsburg, NJ 08865
    4Aduro BioTech, Inc., Berkeley, CA 94710
    Abstract
    Human BDCA3+ dendritic cells (DCs), the proposed equivalent to mouse CD8α+ DCs, are widely thought to cross present antigens on MHC class I (MHCI) molecules more efficiently than other DC populations. If true, it is unclear whether this reflects specialization for cross presentation or a generally enhanced ability to present antigens on MHCI. We compared presentation by BDCA3+ DCs with BDCA1+ DCs using a quantitative approach whereby antigens were targeted to distinct intracellular compartments by receptor-mediated internalization. As expected, BDCA3+ DCs were superior at cross presentation of antigens delivered to late endosomes and lysosomes by uptake of anti-DEC205 antibody conjugated to antigen. This difference may reflect a greater efficiency of antigen escape from BDCA3+ DC lysosomes. In contrast, if antigens were delivered to early endosomes through CD40 or CD11c, BDCA1+ DCs were as efficient at cross presentation as BDCA3+ DCs. Because BDCA3+ DCs and BDCA1+ DCs were also equivalent at presenting peptides and endogenously synthesized antigens, BDCA3+ DCs are not likely to possess mechanisms for cross presentation that are specific to this subset. Thus, multiple DC populations may be comparably effective at presenting exogenous antige

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • United States Patent Application 20130101593
      Kind Code A1
      KELER; Tibor ; et al. April 25, 2013

      --------------------------------------------------------------------------------
      ANTIBODIES THAT BIND HUMAN DENDRITIC AND EPITHELIAL CELL 205 (DEC-205)

      Abstract
      Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

      --------------------------------------------------------------------------------
      Inventors: KELER; Tibor; (Ottsville, PA) ; HE; Lizhen; (Allentown, PA) ; RAMAKRISHNA; Venky; (Riegelsville, PA) ; VITALE; Laura A.; (Doylestown, PA)
      Applicant: Name City State Country

      Celldex Therapeutics Inc.;
      Needham
      MA
      US

      Sentiment: Strong Buy

    • Celldex's employees are prolific authors!

 
CLDX
14.42+0.23(+1.62%)Sep 17 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.